Articles tagged with Drug Studies
A clinical trial led by Professor Robert Bals found that azelastine nasal spray significantly reduced the risk of SARS-CoV-2 infection by 66%. The treatment group showed fewer symptomatic infections and lower respiratory rates compared to the placebo group.
A new study published in The New England Journal of Medicine and the European Heart Journal finds that beta blockers, commonly prescribed after a heart attack, provide no clinical benefit for patients with preserved heart function. Women treated with beta blockers had a higher risk of death, heart attack, or hospitalization for heart f...
A clinical trial led by Tohoku University has found that lubiprostone can prevent the decline of renal function in patients with chronic kidney disease. The study evaluated the effects of lubiprostone on kidney function and found that it improves mitochondrial function, which exerts a renoprotective effect.
A new class of targeted therapy showed promise in treating head and neck squamous cell carcinoma (HNSCC) in pet cats, with 35% of patients experiencing controlled disease. The drug, which targets the transcription factor STAT3, also raised levels of PD-1, a protein associated with an immune response to cancer.
Research from the University of South Australia finds that ibuprofen and paracetamol drive antibiotic resistance when used individually, but amplifying it when combined. The study also reveals that common bacteria like E. coli become highly resistant to antibiotics and multiple other medications.
A new RP-HPLC method has been developed and validated for the analysis of orlistat, a widely used anti-obesity drug. The method ensures accurate quantification and is fully compliant with International Council for Harmonisation (ICH) guidelines, reducing solvent use and analysis time.
A new imaging approach allows researchers to visualize how dual-acting diabetes and obesity drugs like tirzepatide interact with cells in the pancreas and brain. The tool, called daLUXendins, provides insight into the metabolic effects triggered by these drugs, which stimulate both GLP-1R and GIPR receptors.
Researchers from Australia and China have found nine high-priority pathogens in aircraft lavatory wastewater, including some resistant to multiple drugs. The study suggests that monitoring aircraft wastewater could provide an early warning system for the spread of antimicrobial-resistant superbugs.
Researchers have found a way to rearrange atoms in a new generation of malaria drugs to make them more soluble, maintaining their effectiveness against drug-resistant parasites. This breakthrough could lead to an effective successor to artemisinin-based combination therapy.
Researchers developed a deep learning model to predict ADRs using molecular structures, achieving high accuracy in detecting rare effects and minimal risk for novel molecules. The model demonstrated potential as a decision-support tool in early-phase drug discovery and regulatory safety monitoring.
A recent University of Michigan study found that nonmedical use of prescription ADHD drugs among adolescents has dropped from 10% in 2005 to 6% in 2023. Lifetime medical use also increased slightly during the same period, but overall trends suggest a decrease in misusing these prescriptions.
Researchers have developed a groundbreaking method to observe lysosomes in live suspended cells—quantitatively, in 3D, and without the use of chemical labels. The technology uses holographic tomography in flow cytometry configuration (HTFC) to identify morphological and spatial lysosomal changes in models of lysosomal storage diseases.
Researchers Dr. Sharday Mosurinjohn and Dr. Richard Ascough critique the 'psychedelic mysteries hypothesis' in a new article, arguing that it relies on circumstantial evidence rather than solid historical scholarship. They advocate for responsible curiosity and a focus on living traditions to unlock psychedelic wisdom.
Researchers at Kyoto University have discovered a novel analgesic called ADRIANA, which targets the α2B-adrenoceptor and exerts its effect without causing cardiovascular instability. The compound has shown highly promising results in non-clinical studies and early clinical trials.
A new treatment for corneal scarring is being developed by University of Houston optometry researcher Tarsis G. Ferreira. The treatment uses a natural protein called decorin to block scarring and unwanted blood vessel growth, offering hope for people with injured corneas.
Researchers from FAU's Schmidt College of Medicine recommend using high-potency statins as the primary pharmacologic approach in treating and preventing cardiovascular disease. Lifestyle changes, such as regular physical activity and a healthy diet, are also crucial in reducing cardiovascular risk.
Researchers used an AI model to reassess a completed clinical trial for an Alzheimer's disease drug, finding it slowed cognitive decline by 46% in early-stage patients. The AI model predicts patient progression and allows for more precise selection of trial participants, potentially reducing the cost of developing new medicines.
Dr. Mirko Manchia's groundbreaking research identifies genetic markers predicting treatment response in bipolar patients, enabling precision medicine approaches to transform psychiatric care. He envisions a future where genetic testing becomes routine in psychiatric care.
Researchers have identified a hidden molecular mechanism involving two proteins that allows tumors to resist treatment. A new gelatin-based nanoparticle has been developed to shut down both proteins simultaneously, showing promising results in early studies with mice.
Clinical trials show sutezolid and delpazolid are safer alternatives to linezolid for treating drug-resistant TB, with no cases of nerve damage or blood toxicity reported. The findings suggest these drugs could replace linezolid in treatment regimens.
A new study highlights major hurdles for multinational clinical trials in Europe, including differences in timelines and processing times between countries. Researchers found that the UK made significant gains in efficiency during the pandemic, while non-UK countries lagged behind.
A team of researchers proposes a novel adaptive platform trial fund to accelerate ALS drug development. The study outlines a financing model that merges efficiencies with an innovative royalty-based investment structure, drawing on data from the HEALEY ALS Platform Trial. This new approach could transform how diseases like ALS are addr...
Researchers have discovered an oral drug called MA-5 that can improve both heart and muscle problems in patients with Barth syndrome, a rare genetic disorder. The drug boosts cellular energy production by up to 50% and protects cells from oxidative stress-induced death, addressing the underlying cause of the disease.
UVA Health received two anonymous $25 million estate gifts to support the Paul and Diane Manning Institute of Biotechnology. The institute will develop new treatments for hard-to-treat diseases with a state-of-the-art biomedical research facility expected to drive economic growth in Central Virginia.
A new study from Karolinska Institutet found that biological drugs used to treat severe asthma do not completely eradicate inflammatory cells. Researchers discovered an increase in blood levels of these cells during treatment, which could explain why inflammation often returns when treatment is tapered or discontinued. The study aims t...
A common medication used for autoimmune diseases has been found to be effective in treating giant cell arteritis, with nearly half of patients achieving sustained remission. The treatment reduces dependence on glucocorticoids, a common but side-effect-ridden option.
The experimental drug SANA has been shown to prevent fat accumulation, treat existing obesity, and reverse associated metabolic disorders. In animal tests, it activated thermogenesis through an unconventional mechanism, targeting adipose tissue cells to produce heat without involving the UCP1 protein.
Researchers at University of Cologne have discovered a previously unknown mechanism that explains why many patients with aggressive B-cell lymphoma don't respond to CAR-T cell therapy. Combining this innovative treatment with CSF1R inhibitors improves its effectiveness, according to the study published in Cancer Cell.
Researchers discover iguratimod, a rheumatoid arthritis drug, effectively treats excessive COVID-19 inflammation in mice by maintaining antiviral immune responses. The study provides hope for patients with severe COVID-19-related cytokine storms.
Researchers have discovered that nicotinamide riboside supplementation significantly improves NAD+ levels, reducing arterial stiffness, skin ulcer area, and kidney dysfunction. This breakthrough offers new hope for patients with Werner syndrome who lack effective treatment options.
Long-term data from the Phase 1/2 study of zigakibart demonstrate sustained proteinuria remission, stable kidney function, and a reassuring safety profile in patients with IgA nephropathy. The treatment also led to reductions in serum immunoglobulins, consistent with APRIL pathway inhibition.
The annual Alzheimer's disease drug development pipeline report, led by Dr. Jeffrey Cummings, highlights an increase in active clinical trials and promising drugs, offering reason for optimism. The report assesses 138 drugs currently being studied and notes the growing importance of biomarkers in clinical trials.
The S2302 Pragmatica-Lung trial found that the investigational combination of ramucirumab and pembrolizumab did not extend overall survival compared to standard-of-care treatments. The study enrolled a highly representative population of patients, establishing it as a paradigm-shifting model for large randomized studies.
A WVU microbiology student has discovered a new species of fungus, Periglandula clandestina, that produces effects similar to the semisynthetic drug LSD. The fungus is highly efficient at making ergot alkaloids, which can be used therapeutically to treat conditions like depression and addiction.
A Kennedy Krieger researcher's work on a promising oral drug, leriglitazone, has shown it can slow the progression of cerebral adrenoleukodystrophy (cALD) in all 11 trial participants. Nearly half of boys treated with the medication appeared to halt disease progression entirely.
DB-1310, a HER3-targeted antibody-drug conjugate, has shown real potential as a new treatment option for patients with advanced solid tumors that have progressed after standard therapies. In an international clinical trial, DB-1310 demonstrated significant tumor shrinkage and delayed cancer growth in 44% of EGFR-mutant NSCLC patients.
A new four-drug combination, DKRd, has emerged as a highly effective and safe treatment for newly diagnosed multiple myeloma patients. The ADVANCE clinical trial shows that 59% of patients treated with DKRd were MRD-negative after eight cycles of treatment, compared to 36% of KRd-treated patients.
The research aims to improve the survivability of wounded soldiers, enhance combat safety, and accelerate postoperative recovery in a multicenter pivotal clinical study. OYE's technology has shown promise in reducing mortality rates, lowering healthcare costs, and improving surgical workflow efficiency.
The ISSCR has assembled an international consortium to support the adoption of human stem cell-derived disease models for drug discovery and development. This initiative aims to reduce R&D costs and accelerate therapy development, aligning with efforts by regulatory bodies such as the FDA, NIH, and European Commission.
Researchers found that an inexpensive HIV drug can improve vision in patients with diabetic macular edema (DME) more effectively and at a lower cost than existing treatments. The drug, lamivudine, is taken orally and may represent a game-changing option for millions of patients worldwide.
A phase 3 trial announced today demonstrated lorundrostat's safety and effectiveness in reducing blood pressure in patients with resistant hypertension. The treatment, which blocks the production of aldosterone from the adrenal glands, achieved clinically meaningful and sustained reductions in systolic blood pressure.
The Center for Research Innovation in Biotechnology (CRIB) has developed a comprehensive database of active pharmaceutical ingredients with evidence of clinical testing. The database provides valuable information on drug discovery and development, including pricing, sponsors, and intended clinical applications.
Researchers found that denosumab increases tumour-infiltrating immune cells in early-stage breast cancer patients, particularly in type B luminal tumours. This increase is associated with a potential boost to the anti-tumor immune response and offers a valuable avenue for clinical interest.
A study reveals pharmacy care is perceived differently by diverse populations, with notable gaps in communication for patients with disabilities. The research highlights the importance of effective communication and accessible spaces for pharmacists to provide high-quality care.
A new head-to-head study has shown that tirzepatide results in around 50% more weight loss than semaglutide in adults with obesity. The study found that tirzepatide led to an average weight loss of 20.2%, significantly higher than the 13.7% achieved with semaglutide.
A real-world study of 1,752 patients with stage III or IV ovarian cancer found that adding bevacizumab to chemotherapy improved overall survival for those with advanced disease and residual cancer. Benefits were mostly seen in high-risk patients, not the general population.
A systematic review of available evidence found GLP-1 RAs lead to significant weight loss and improved blood sugar control in adults with severe mental illness. The analysis also showed that these medications were not associated with a worsening of mental state or suicidal behaviour.
Researchers found that patients taking HIV drugs called NRTIs are substantially less likely to develop Alzheimer's disease. The study, led by Jayakrishna Ambati, analyzed data from two large health insurance databases and determined a significant reduction in Alzheimer's risk among patients on NRTIs.
A clinical trial finds that moxidectin is more effective than current treatment ivermectin for lymphatic filariasis, a disease affecting millions in Africa. Moxidectin has a persistent effect and may require fewer rounds of treatment, potentially accelerating its elimination.
Rasika Dias, a renowned chemist at UTA, has been named a 2025 fellow of the Royal Society of Chemistry for his groundbreaking contributions to chemical sciences. He is the second chemistry faculty member to receive this honor.
A new gene therapy has successfully restored immune function in nine children with severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder. The treatment has eliminated symptoms and reduced severe infections, offering a life-changing benefit to these patients.
A Phase Ia/Ib trial found that zongertinib demonstrated clinical benefits for patients with advanced HER2-mutant non-small cell lung cancer, particularly those with specific HER2 mutations. The treatment showed a 71% objective response rate and manageable side effects.
A global research initiative analyzing data from nearly 2 million people in diverse populations worldwide has uncovered multiple new genes associated with osteoarthritis. The study also identified key genetic pathways and 69 genes whose protein products are targeted by approved drugs, paving the way for repurposed treatments.
The International Progressive MS Alliance has awarded €100,000 to three development project teams to plan clinical trials. The projects focus on developing new treatments for progressive MS, including exercise-induced fatigability, neural stem cell therapy, and salbutamol treatment.
A phase II trial found that pembrolizumab significantly reduced recurrence in patients with DNA mismatch repair-deficient early-stage solid cancers who had detectable circulating tumor DNA after surgery. The study suggests that using ctDNA to guide immunotherapy may help prevent relapse in high-risk patients.
A novel topical BRAF inhibitor gel called LUT014 has been shown to significantly reduce the severity of an acne-like rash in patients undergoing anti-EGFR therapies for colorectal cancer. The treatment's safety and effectiveness have been confirmed, offering a potential solution to managing this common side effect.
The treatment demonstrated early signals of efficacy, with 65.7% of patients experiencing lasting stable disease, and was generally well-tolerated, with most adverse events being mild and manageable.
A clinical trial found that LUT014, a topical BRAF inhibitor, significantly reduced the severity of acne-like skin rashes caused by targeted therapy for colorectal cancer. Patients who received LUT014 had improved quality of life and were able to continue receiving their cancer treatment with reduced side effects.
The study shows that Huo Xue Tong Luo capsule inhibits osteoclast formation and protects bone mass in ovariectomized mice. The PI3K-AKT signaling pathway is targeted to prevent bone loss induced by ovariectomy.
A study published in Food Chemistry: Molecular Sciences found that cinnamaldehyde in cinnamon activates receptors controlling medication clearance, raising concerns about potential interactions. Researchers recommend consulting a doctor before using cinnamon as a dietary supplement to avoid rapid clearance of prescription medicines.